Medical Developments International Ltd's Chairman sells shares, time to worry?

The Medical Developments International Ltd (ASX:MVP) Chairman has sold shares.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

There is a rising suspicion in the market these days of businesses when leadership sell some of their shares.

There's usually only one reason management buy shares – they think it's good value. But there's usually a myriad of reasons for selling such as divorce, needing cash for X and so on.

Today, Medical Developments International Ltd (ASX: MVP) announced that its Chairman, Mr David Williams, had sold five million shares off-market at $7.50 per share. Selling a total of $37.5 million is not small change.

Medical Developments International included a quote from Mr Williams explaining his reasoning about why he sold, "MVP recently completed a three-week roadshow where 48 financial institutions from Europe, Asia and Australia were presented the MVP story. As a result of those meetings there was strong demand for shares and for more liquidity from a number of financial institutions through Jeffries Securities of Hong Kong and Bell Potter in Australia.

"I remain MVP's biggest shareholder and own 8,671,045 (14.67% of MVP stock). As Chairman I am delighted and proud of the progress MVP is making and I view the strong demand from financial institutions as a vote of confidence in the future of MVP. We are quickly building a global business and a global shareholder base. I am told the shares sold yesterday went to funds in Australia, US and UK."

Foolish takeaway

It's probably a good thing that financial institutions want a piece of Medical Developments, so perhaps it's a good thing that Mr Williams sold some shares, selling over a third of the shares is a big move. However, only the future can tell whether the timing of the sale will lead to a price decline as other companies have seen in the past.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »